Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation (ADPT) Revenue
Annual & quarterly revenue history · segment & region breakdown
ADPT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAdaptive Biotechnologies Corporation trailing twelve-month (TTM) revenue is $0.30B, an increase of 54.77% year-over-year from $0.28B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.28B | +$0.10B | +54.77% |
| 2024-12-31 | $0.18B | +$0.01B | +5.10% |
| 2023-12-31 | $0.17B | -$0.02B | -8.11% |
| 2022-12-31 | $0.19B | +$0.03B | +20.06% |
| 2021-12-31 | $0.15B | +$0.06B | +56.88% |
| 2020-12-31 | $0.10B | +$0.01B | +15.65% |
| 2019-12-31 | $0.09B | +$0.03B | +52.83% |
| 2018-12-31 | $0.06B | +$0.02B | +44.77% |
| 2017-12-31 | $0.04B | — | — |
Compare revenue vs peers
BiotechnologyCompare ADPT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Adaptive Biotechnologies Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Adaptive Biotechnologies Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Adaptive Biotechnologies Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ADPT revenue · 4 questionsADPT's trailing twelve-month (TTM) revenue is $0.30B. That is an increase of 54.77% year-over-year from $0.28B in FY2025.
▸ Source: FMP · Adaptive Biotechnologies Corporation SEC filings · GAAP · Adaptive Biotechnologies Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026